Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
Proton RahmanIain B McInnesAtul A DeodharLarissa Valor-MéndezPhillip J MeaseMay ShawiDaniel J CuaJonathan P SherlockAlexa P KollmeierXie L XuShihong ShengChristopher T RitchlinDennis G McGonaglePublished in: Clinical rheumatology (2024)
ClinicalTrials.gov ( https://clinicaltrials.gov ) NCT03158285; Registered: May 16, 2017. Key Points • At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER/DR). • Achieving ER was associated with achieving DR and vice versa through the end of study. • Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported outcomes.